» Articles » PMID: 38401539

Clonal Differences Underlie Variable Responses to Sequential and Prolonged Treatment

Overview
Journal Cell Syst
Publisher Cell Press
Date 2024 Feb 24
PMID 38401539
Authors
Affiliations
Soon will be listed here.
Abstract

Cancer cells exhibit dramatic differences in gene expression at the single-cell level, which can predict whether they become resistant to treatment. Treatment perpetuates this heterogeneity, resulting in a diversity of cell states among resistant clones. However, it remains unclear whether these differences lead to distinct responses when another treatment is applied or the same treatment is continued. In this study, we combined single-cell RNA sequencing with barcoding to track resistant clones through prolonged and sequential treatments. We found that cells within the same clone have similar gene expression states after multiple rounds of treatment. Moreover, we demonstrated that individual clones have distinct and differing fates, including growth, survival, or death, when subjected to a second treatment or when the first treatment is continued. By identifying gene expression states that predict clone survival, this work provides a foundation for selecting optimal therapies that target the most aggressive resistant clones within a tumor. A record of this paper's transparent peer review process is included in the supplemental information.

Citing Articles

Single-Cell Lineage Tracing and Clonal State-Fate Analysis.

Rodriguez Fraticelli A, Sanchez P Methods Mol Biol. 2025; 2886:65-84.

PMID: 39745636 DOI: 10.1007/978-1-0716-4310-5_4.


Non-genetic differences underlie variability in proliferation among esophageal epithelial clones.

Reyes Hueros R, Gier R, Shaffer S PLoS Comput Biol. 2024; 20(10):e1012360.

PMID: 39466790 PMC: 11573201. DOI: 10.1371/journal.pcbi.1012360.


The evolutionary theory of cancer: challenges and potential solutions.

Laplane L, Maley C Nat Rev Cancer. 2024; 24(10):718-733.

PMID: 39256635 PMC: 11627115. DOI: 10.1038/s41568-024-00734-2.


RNA Polymerase II hypertranscription at histone genes in cancer FFPE samples.

Henikoff S, Zheng Y, Paranal R, Xu Y, Greene J, Henikoff J bioRxiv. 2024; .

PMID: 38559075 PMC: 10979862. DOI: 10.1101/2024.02.28.582647.

References
1.
Menzies A, Long G, Murali R . Dabrafenib and its potential for the treatment of metastatic melanoma. Drug Des Devel Ther. 2012; 6:391-405. PMC: 3523565. DOI: 10.2147/DDDT.S38998. View

2.
Acheampong K, Schaff D, Emert B, Lake J, Reffsin S, Shea E . Subcellular Detection of SARS-CoV-2 RNA in Human Tissue Reveals Distinct Localization in Alveolar Type 2 Pneumocytes and Alveolar Macrophages. mBio. 2022; 13(1):e0375121. PMC: 8822351. DOI: 10.1128/mbio.03751-21. View

3.
Menon D, Das S, Krepler C, Vultur A, Rinner B, Schauer S . A stress-induced early innate response causes multidrug tolerance in melanoma. Oncogene. 2014; 34(34):4448-59. PMC: 4442085. DOI: 10.1038/onc.2014.372. View

4.
Marine J, Dawson S, Dawson M . Non-genetic mechanisms of therapeutic resistance in cancer. Nat Rev Cancer. 2020; 20(12):743-756. DOI: 10.1038/s41568-020-00302-4. View

5.
Beaumont K, Hill D, Daignault S, Lui G, Sharp D, Gabrielli B . Cell Cycle Phase-Specific Drug Resistance as an Escape Mechanism of Melanoma Cells. J Invest Dermatol. 2016; 136(7):1479-1489. DOI: 10.1016/j.jid.2016.02.805. View